DNUT: Krispy Kreme Raises Its Outlook as the Turnaround Continues
Krispy Kreme lifted its full-year revenue forecast, but declining quarterly revenue and a net loss show the turnaround remains unfinished.
Read the story
AMTX: Aemetis Reports a Profit With a Tax-Credit Boost
Aemetis reported third-quarter revenue of $88.2 million and net income of $5.2 million. Clean-fuel tax credits and a first-half adjustment complicate the run-rate picture.
ELPW: Elong Power’s Energy-Storage Agreement Still Needs Execution
Elong Power announced a three-year energy-storage cooperation agreement with anticipated procurement of at least RMB 2 billion. Actual orders remain the next test.
LABT: Lakewood-Amedex Removes a Source of Potential Dilution
Lakewood-Amedex redeemed its remaining Series C convertible preferred shares. The financing change removes one source of potential dilution, but uses cash.
Four Stocks Surging Today: Why LABT, ELPW, AMTX and DNUT Are on the Move
LABT, ELPW, AMTX and DNUT jumped after financing, energy-storage and earnings news. Here’s what investors should know about the announcements and risks.
Penny StocksIMNN: ThermoDox Deal Gives a Written-Off Asset a New Path
IMUNON’s proposed ThermoDox sale offers contingent future value while management focuses on its Phase 3 ovarian-cancer program.
Penny StocksKTTA: Pasithea Approaches Its October 23 Cancer-Data Presentation
An upcoming ESMO presentation gives Pasithea a defined clinical event as its shares rebound. The actual data will matter more than anticipation.
Penny StocksSHFS: Nasdaq Gives Safe Harbor More Time as Shares Rebound
A new compliance deadline gives Safe Harbor breathing room. Restoring its bid price and strengthening the business remain separate challenges.
Penny StocksNUAI: New Era’s AI Data-Center Plan Faces the Tenant Test
Power arrangements and credit support advance New Era’s infrastructure plan. Signed leases and project economics are the next commercial tests.
Penny StocksPDSB: A New Board as PDS Biotech Prepares Its Next Cancer-Trial Push
A board refresh gives PDS Biotechnology a timely business milestone. Clinical planning, financing and eventual patient evidence remain the investment tests.
Penny StocksDFSC: From Army Demonstrations to Commercial Orders—DEFSEC’s Next Test
DEFSEC’s corporate update puts product readiness and sales execution in focus. The key question is whether demonstrations and production become profitable customer orders.
Penny StocksXHLD: TEN Holdings Takes Its Digital-Experience Platform to Investors
Investor presentations put TEN Holdings’ strategy in the spotlight. Customer adoption, revenue quality and financial execution are the more durable tests.